Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciara L Freeman

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Open Forum Infectious Diseases|October 16, 2024
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B ReactivationGuy Handley, Amanda Yepes, Eva Eliassen, et al.
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
Blood|September 22, 2025
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapyMark B Meads, Xiaohong Zhao, David R Noyes, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Relapse timing is associated with distinct evolutionary dynamics in DLBCLLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Transplantation and Cellular Therapy|June 18, 2026
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesNathan H Parker, Jongphil Kim, Morgan Bean, et al.
Blood Cancer Journal|April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy ConsortiumAimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
Blood|December 9, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomesCiara L Freeman, Jerald Noble, Meghan Menges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2023
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell LymphomaLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Open Forum Infectious Diseases|October 16, 2024
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B ReactivationGuy Handley, Amanda Yepes, Eva Eliassen, et al.
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
Blood|September 22, 2025
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapyMark B Meads, Xiaohong Zhao, David R Noyes, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Relapse timing is associated with distinct evolutionary dynamics in DLBCLLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Transplantation and Cellular Therapy|June 18, 2026
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesNathan H Parker, Jongphil Kim, Morgan Bean, et al.
Blood Cancer Journal|April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy ConsortiumAimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
Blood|December 9, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomesCiara L Freeman, Jerald Noble, Meghan Menges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2023
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell LymphomaLaura K Hilton, Henry S Ngu, Brett Collinge, et al.
Pageof 7